Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation
Authors: Robert G. Hart, Lesly A. Pearce, Maria I. Aguilar
Journal: Annals of Internal Medicine (2007)

Letters16 October 2007Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial FibrillationRobert G. Hart, MD, Lesly A. Pearce, MS, and Maria I. Aguilar, MDRobert G. Hart, MDFrom the University of Texas Health Science Center, San Antonio, TX 78229-3900; Minot, ND 58703; and Mayo Clinic Scottsdale, Phoenix, AZ 85054., Lesly A. Pearce, MSFrom the University of Texas Health Science Center, San Antonio, TX 78229-3900; Minot, ND 58703; and Mayo Clinic Scottsdale, Phoenix, AZ 85054., and Maria I. Aguilar, MDFrom the University of Texas Health Science Center, San Antonio, TX 78229-3900; Minot, ND 58703; and Mayo Clinic Scottsdale, Phoenix, AZ 85054.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-8-200710160-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The recently published, randomized Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) Study compared adjusted-dose warfarin (target international normalized ratio, 2.0 to 3.0) with aspirin (75 mg/d) in 973 patients with atrial fibrillation who were 75 years of age or older (mean age, 81.5 years) and were managed by general practitioners in the United Kingdom (1). The study's important results indicate that the relative efficacy and safety of warfarin for stroke prevention can be extended to very elderly patients who are managed by nonspecialists. Because the BAFTA Study seems likely to be the last large trial comparing ...References1. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503. [PMID: 17693178] CrossrefMedlineGoogle Scholar2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. [PMID: 17577005] LinkGoogle Scholar3. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9. [PMID: 2563096] CrossrefMedlineGoogle Scholar4. Petersen P, Boysen G. Prevention of stroke in atrial fibrillation. N Engl J Med. 1990;323:482. Google Scholar5. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-21. [PMID: 9679792] CrossrefMedlineGoogle Scholar6. Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34:295-8. [PMID: 16776915] MedlineGoogle Scholar7. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62. [PMID: 7901582] CrossrefMedlineGoogle Scholar8. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958-64. [PMID: 10514159] CrossrefMedlineGoogle Scholar9. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91. [PMID: 7907677] MedlineGoogle Scholar10. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997;28:1015-21. [PMID: 9158644] CrossrefMedlineGoogle Scholar11. ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12. [PMID: 16765759] CrossrefMedlineGoogle Scholar12. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557-66. [PMID: 15489085] CrossrefMedlineGoogle Scholar13. Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Xinos K, Vassilopoulou S, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation—a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006;17:48-52. [PMID: 16378886] CrossrefMedlineGoogle Scholar14. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36:151-6. [PMID: 17175564] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the University of Texas Health Science Center, San Antonio, TX 78229-3900; Minot, ND 58703; and Mayo Clinic Scottsdale, Phoenix, AZ 85054.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMeta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation Robert G. Hart , Lesly A. Pearce , and Maria I. Aguilar Metrics Cited ByVorhofflimmernHemorrhagic transformation and stroke recurrence in children with cardiac disease receiving antithrombotic therapy for secondary stroke preventionControversies: Stroke Prevention in Chronic Kidney Disease2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical SettingsGuía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)Mechanical valve replacement without anticoagulation: a case reportEffects of rivaroxaban on activated clotting time in catheter ablation for atrial fibrillation in Chinese patientsDifferences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE-AF registry studyDoes the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysisAtrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients: Subanalysis of the ANAFIE (All Nippon AF In the Elderly) RegistryPractice Gap in Atrial Fibrillation Oral Anticoagulation Prescribing at Emergency Department Home DischargeImpact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With RivaroxabanAntikoagulation unter erschwerten BedingungenDirect comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillationAntikoagulation bei VorhofflimmernSequential approach for the detection of atrial fibrillation in patients with cryptogenic strokeDirect oral anticoagulation and mortality in moderate to high-risk atrial fibrillationStroke prevention in atrial fibrillation: State of the artUse of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case reportBiomarkers Associated with Bleeding Risk in the Setting of Atrial FibrillationNOACs only for those who cannot tolerate a VKA: where is the evidence?Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, AustraliaDesign and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow-up cohort studyRisk of thromboembolic complications in adult congenital heart disease: A literature reviewNational Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving XabansSpecific Treatment of Acute Intracerebral HemorrhageReal-World Safety of AnticoagulantsStroke prevention within primary care: management of atrial fibrillation using oral anticoagulationAnticoagulation Resumption After Intracerebral HemorrhageAtrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreatedImpact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarinA Systematic Review of the Hemorrhage Risk for Patients on Antithrombotic Medication after Dental ProceduresOral AnticoagulationStroke Prevention in Atrial Fibrillation: Focus on Asian PatientsThe future of atrial fibrillation management: integrated care and stratified therapyNon-vitamin K antagonist oral anticoagulants for heart diseasesAn Update on Anticoagulation in Atrial FibrillationApixaban Pharmacokinetics at Steady State in Hemodialysis PatientsQuality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF RegistryNuevos anticoagulantes orales en pacientes con enfermedad renal crónicaNew oral anticoagulants in patients with chronic kidney diseaseNon-major bleeding with apixaban versus warfarin in patients with atrial fibrillationRivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial FibrillationAtrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary InterventionConsequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillationStroke prevention in atrial fibrillation: Past, present and futureJuvenile Stroke: A Practice-Oriented OverviewA Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) RegistryReal-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean PatientsTotal Cerebral Blood Flow in Patients with Cardioembolic Stroke: Is It Clinically Meaningful?2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSReasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarinGemeinsam mit dem Patienten klug entscheidenHistory of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialIschaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysisUse of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke IncidenceAnticoagulant Therapy-Induced Gallbladder Hemorrhage after Cardiac Valve ReplacementSekundärprophylaxe mit oralen AntikoagulanzienThe Impact of Novel Anticoagulants2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview: A professional societal overview from the American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overviewGastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation controlSubclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal OverviewParoxysmal atrial fibrillation in young cryptogenic ischemic stroke: A 3-week ECG Holter monitoring studyThromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical AlgorithmSafety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approachEfficacy and Safety of Oral Anticoagulants Versus Aspirin for Patients With Atrial FibrillationIschemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and WarfarinA cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocolSecular Trends in Ischemic Stroke Subtypes and Stroke Risk Factors2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial FibrillationEdoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment ComparisonsAntithrombotic Treatment in Patients With Heart Failure and Associated Atrial Fibrillation and Vascular DiseasePrevalence of atrial fibrillation in intracerebral hemorrhageA Pint of Sweat Will Save a Gallon of BloodCardiac Procedures to Prevent Stroke: Patent Foramen Ovale Closure/Left Atrial Appendage Occlusion5. Secondary Prevention of Cerebral Infarction -Most Useful Antithrombotic Therapy for Japanese PatientsCost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic OdysseyStroke and Bleeding Risk in Atrial FibrillationImproved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic StrokeWhich Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based ChoicesValidation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillationRelation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillationOral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery DiseaseCurrent Approaches to Anticoagulation for Reducing Risk of Atrial Fibrillation–Related StrokeKlinische Studien zu neuen direkten oralen AntikoagulanzienOverview of pathophysiology and management of AFTop practice-changing articles over the last two yearsAssessing bleeding risk in patients taking anticoagulantsHospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcomeNew oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figuresThe Decline Effect in Cardiovascular Medicine: Is the Effect of Cardiovascular Medicine and Stent on Cardiovascular Events Decline Over the Years?Clinical trials with new oral anticoagulantsSupporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: The STOP STROKE in AF study. Protocol for a cluster randomised controlled trialAntithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valvesSafety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non–ST elevation myocardial infarctionAntiplatelet DrugsHead-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What's next?Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStudy protocol: the DESPATCH study: Delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcareBleeding risk with oral anticoagulation - new frontiers and new questionsWhat are the costs of atrial fibrillation?Apixaban in Patients with Atrial FibrillationNeue orale Antikoagulanzien beim VorhofflimmernCanadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and FlutterComprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic optionsSafety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial FibrillationRecent Progress in Antithrombotic Therapy for Atrial FibrillationAntithrombotic therapy in secondary preventionAge as a Risk Factor for Stroke in Atrial Fibrillation PatientsAntithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular eventsReplacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational studyAssessment of endothelial (dys)function in atrial fibrillationWarfarinThe management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal surveyThe pathophysiology and management of atrial fibrillation"Triple Therapy" or Triple Threat? 16 October 2007Volume 147, Issue 8Page: 590-592KeywordsAtrial fibrillationElderlySafetySafety studiesStrokeThromboembolism ePublished: 16 October 2007 Issue Published: 16 October 2007 CopyrightCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...